Axonics

Axonics Equity

The The Equity of Axonics (AXNX) as of Nov 19, 2026 is 637.56 M USD. In the previous year, The Equity was 570.14 M USD — a change of 11.83% (higher).

Equity

637.56 MUSD

YoY

11.83%

Last updated:

In 2023, Axonics's equity was 637.56 M USD, a 11.83% increase from the 570.14 M USD equity in the previous year.

The Axonics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
-49.43 M USD
Jan 1, 2017
-66.42 M USD
Jan 1, 2018
143.28 M USD
Jan 1, 2019
183.00 M USD
Jan 1, 2020
287.37 M USD
Jan 1, 2021
482.44 M USD
Jan 1, 2022
570.14 M USD
Jan 1, 2023
637.56 M USD
The Axonics Equity history
YEAREquityYoY
637.56 MUSD+11.83%
570.14 MUSD+18.18%
482.44 MUSD+67.88%
287.37 MUSD+57.03%
183.00 MUSD+27.73%
143.28 MUSD-315.71%
-66.42 MUSD+34.37%
-49.43 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Axonics Stock analysis

What does Axonics do? Axonics Modulation Technologies Inc. is a medical device company that was founded in 2013 and is headquartered in Irvine, California. The company specializes in the development and marketing of innovative therapy devices for the treatment of bladder dysfunction and bowel diseases. Axonics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Axonics's Equity

Axonics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Axonics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Axonics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Axonics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Axonics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Axonics stock

The Equity of Axonics is 637.56 M USD in 2023.

The Equity of Axonics changed from 570.14 M USD to 637.56 M USD, representing a 11.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Axonics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Axonics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Axonics

All Key Metrics — Axonics